Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Single Rising Dose Study of Empagliflozin in Healthy Japanese Men
NCT02182453Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2008
- Primary completion
- Aug 2008
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing BI 10773 with Placebo (2 arms). Primary endpoints: Number of patients with adverse events up to 7 days, Number of patients with abnormal changes in laboratory parameters at Day 7 and 3 more. Started Jun 2008; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02182453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182453.